Larimar Therapeutics, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 61.47 | -100% | -3.73 | -100% |
| P/S |
|
0 | 33.58 | -100% |
|
|
| P/BV |
|
2.3 | 4.79 | -52.02% |
|
|
| P/FCF |
|
-4.03 | 60.06 | -106.71% |
|
|
| Ev/Ebitda |
|
-4.02 | -17.26 | -76.7% |
|
|
| Ev/S |
|
0 | 22.5 | -100% |
|
|
| Ev/FCF |
|
-4.96 | 69 | -107.19% |
|
|
| E/P |
|
-0.2729 | 0.0168 | -1720.34% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
0 | 4.5 | -100% | 0 | 0% |
| ROE |
|
-45.21 | 9.39 | -581.45% |
|
|
| ROA |
|
-38.51 | 0.1519 | -25451.16% |
|
|
| ROIC |
|
0 | 7.63 | -100% |
|
|
| ROS |
|
0 | -25.64 | -100% |
|
|
| ROCE |
|
-51.1 | 15.19 | -436.49% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.1338 | -3.67 | -96.35% | -0.1341 | -0.2159% |
| Nеt Debt/Ebitda |
|
0.5116 | -4.06 | -112.61% |
|
|
| Debt/Ratio |
|
0.0578 | 0.199 | -70.95% |
|
|
| Debt/Equity |
|
6.67 | 1.54 | 332.51% |
|
|
| Debt/Net Income |
|
-0.1501 | 10.34 | -101.45% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.5399 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.7368 | -100% | ||
| DSI |
|
0 | 0.2331 | -100% |
|
|
| Average dividend growth |
|
0 | 1.07 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.4916 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.32 | -100% |
|
|
| Difference from average difference in sector |
|
-0.5399 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
0/10
|
0 | 76.2 | -100% | ||
| Growth impulse Ebitda in 5 years |
|
79.15 | 44.75 | 76.87% | ||
| Growth impulse Net Income in 5 years |
|
60.3 | -15.36 | -492.58% | ||
| Growth impulse FCF in 5 years |
|
47.59 | -9.39 | -606.82% | ||
| Growth impulse EPS in 5 years |
|
-66.36 | -84.03 | -21.03% |
IP Score
3.09/10
